Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enoxaparin sodium - Sanofi

Drug Profile

Enoxaparin sodium - Sanofi

Alternative Names: Clexane; Decipar; Enoxaparin; Klexane; Levenox; Lovenox; PK 10169; PRY 005; RP 54563; RPY 005

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmuka
  • Developer G.L. Pharma; Italfarmaco; Sanofi
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Myocardial infarction; Thromboembolism; Thrombosis; Unstable angina pectoris
  • Phase III Small cell lung cancer

Most Recent Events

  • 19 Jun 2019 Momenta Pharmaceuticals, Sandoz and Amphastar Pharmaceuticals enters into settlement agreement for litigation related to enoxaparin sodium
  • 08 May 2018 The US District Court of Massachusetts issued the final judgment decision in the patent litigation against Amphastar involving US patent (no. 7,, regarding generic enoxaparin sodium injection in USA.
  • 21 Sep 2017 Phase III development in Small cell lung cancer is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top